NCT06422208View on ClinicalTrials.gov

Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Parkinson Disease
Interventions
BIOLOGICAL

Autologous midbrain dopamine neurons

The autologous midbrain dopamine neurons are a experimental cryopreserved cell product derived from human autologous induced pluripotent stem cells. The autologous midbrain dopamine neurons will be surgically administered into the putamen, unilaterally, in a single surgical session.

Trial Locations (1)

02215

Brigham & Women's Hospital, Boston

Sponsors

Collaborators (1)

Oryon Cell Therapies
All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

Oryon Cell Therapies

UNKNOWN

lead

Penelope J. Hallett, Ph.D.

OTHER

NCT06422208 - Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease | Biotech Hunter | Biotech Hunter